OMERNasdaqPharmaceutical PreparationsFiscal year ends December 31
OMEROS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$16.35+0.15 (+0.93%)
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
49.9%
36M of 72M shares
Institutional holders
172
36 new, 25 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $3.04M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 5,961,792 | 8.20% | 13G (passive) amendment | Jun 30, 2026 |
| / Gregory A. Demopulos, M.D | 5,704,061 | 8.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OMER | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,044,633 | 8.35% | $57.48M | +735,007 | 0.00% |
| Ingalls & Snyder LLC | 3,659,523 | 5.06% | $34.80K | +100,100 | 0.95% |
| UBS Group AG | 3,148,384 | 4.35% | $29.94M | +807,653 | 0.00% |
| Vanguard Capital Management LLC | 3,072,050 | 4.24% | $29.22M | +88,791 | 0.00% |
| State Street Corp | 2,319,906 | 3.20% | $22.06M | +400,331 | 0.00% |
| Geode Capital Management, LLC | 1,914,460 | 2.64% | $18.21M | +162,137 | 0.00% |
| Stifel Financial Corp | 1,836,925 | 2.54% | $17.47M | +5,340 | 0.01% |
| Vanguard Portfolio Management LLC | 962,828 | 1.33% | $9.16M | +244,153 | 0.00% |
| Invesco Ltd. | 751,771 | 1.04% | $7.15M | +571,142 | 0.00% |
| Northern Trust Corp | 727,348 | 1.00% | $6.92M | +163,481 | 0.00% |
| Rock Springs Capital Management LP | 718,499 | 0.99% | $6.83M | New | 0.33% |
| Corient Private Wealth LLC | 659,730 | 0.91% | $6.27M | −141,681 | 0.01% |
| Rubric Capital Management LP | 656,874 | 0.91% | $6.25M | New | 0.06% |
| Charles Schwab Investment Management Inc | 604,633 | 0.84% | $5.75M | +22,121 | 0.00% |
| Bank Of Montreal /Can/ | 568,424 | 0.79% | $5.41M | −2 | 0.00% |
| Vanguard Fiduciary Trust Co | 491,173 | 0.68% | $4.67M | −1,172 | 0.00% |
| Federated Hermes, Inc. | 478,290 | 0.66% | $4.55M | New | 0.01% |
| Clutterbuck Capital Management LLC | 450,000 | 0.62% | $4.28M | +150,000 | 2.43% |
| Two Sigma Investments, LP | 402,662 | 0.56% | $3.83M | +116,188 | 0.00% |
| Morgan Stanley | 394,459 | 0.54% | $3.75M | +76,567 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 172 | 36M | 49.9% | 36 / 68 | 42 / 25 | 7M | 2M |
| Q1 2026 | 162 | 31M | 42.6% | 37 / 62 | 41 / 22 | 7M | 5M |
| Q4 2025 | 151 | 34M | 46.9% | 33 / 61 | 35 / 13 | 9M | 8M |
| Q3 2025 | 133 | 33M | 46.0% | 15 / 57 | 31 / 9 | 6M | 2M |
| Q2 2025 | 127 | 30M | 40.9% | 16 / 44 | 36 / 25 | 5M | 3M |
| Q1 2025 | 137 | 28M | 38.1% | 22 / 35 | 50 / 12 | 3M | 2M |
| Q4 2024 | 128 | 27M | 36.7% | 31 / 49 | 27 / 11 | 3M | 1M |
| Q3 2024 | 108 | 25M | 34.6% | 16 / 27 | 34 / 8 | 5M | 1M |
| Q2 2024 | 104 | 25M | 34.5% | 17 / 24 | 32 / 12 | 1M | 2M |
| Q1 2024 | 99 | 26M | 35.8% | 14 / 28 | 33 / 12 | 2M | 1M |
| Q4 2023 | 97 | 25M | 34.9% | 12 / 27 | 32 / 14 | 1M | 3M |
| Q3 2023 | 100 | 27M | 37.2% | 10 / 33 | 24 / 13 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of OMER | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,172,336 | 3.00% | $20.66M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,877,113 | 2.59% | $17.85M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 831,218 | 1.15% | $7.90M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 788,562 | 1.09% | $9.34M | 0.03% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 640,960 | 0.89% | $6.10M | 1.42% | Jun 30, 2026 |
| Invesco Biotechnology & Genome ETF | 601,237 | 0.83% | $7.12M | 2.52% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 417,582 | 0.58% | $3.97M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 366,516 | 0.51% | $4.05M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 352,679 | 0.49% | $3.89M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 343,807 | 0.47% | $3.80M | 0.02% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 252,978 | 0.35% | $2.41M | 0.02% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 240,842 | 0.33% | $2.29M | 0.15% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 219,522 | 0.30% | $2.60M | 0.31% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 213,047 | 0.29% | $2.35M | 0.01% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 191,200 | 0.26% | $2.11M | 0.11% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gregory A. Demopulos MD | Chairman, CEO & President, Director | 2,250,931 | 3.11% | Jul 24, 2026 |
| David J. Borges | VP, Finance & CAO | 0 | – | Sep 24, 2026 |
| Peter B. Cancelmo | VP, General Counsel | 25,200 | 0.03% | Sep 1, 2026 |
| Arnold C. Hanish | Director | 14,900 | 0.02% | Aug 28, 2026 |
| Thomas J. Cable | Director | 50,067 | 0.07% | Aug 21, 2026 |
| Joseph L. Schocken | Director | 528,082 | 0.73% | Aug 18, 2026 |
| Peter A. Demopulos MD | Director | 372,898 | 0.52% | Jun 22, 2026 |
| Leroy E. MD Hood PhD | Director | 74,390 | 0.10% | Jun 22, 2026 |
| Rajiv Shah | Director | – | – | Jun 22, 2026 |
| Thomas F. Bumol | Director | 10,000 | 0.01% | Jun 22, 2026 |
| Diana T. Perkinson | Director | – | – | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David J. Borges VP, Finance & CAO | Sep 23, 2026 | Sale(10b5-1 plan) | −10,000 | $20.95 | $209.50K | 0 |
| David J. Borges VP, Finance & CAO | Sep 23, 2026 | Option exercise | +10,000 | $15.58 | $155.80K | 10,000 |
| David J. Borges VP, Finance & CAO | Sep 22, 2026 | Option exercise | +5,000 | $2.94 | $14.70K | 10,000 |
| David J. Borges VP, Finance & CAO | Sep 22, 2026 | Option exercise | +5,000 | $3.93 | $19.65K | 5,000 |
| David J. Borges VP, Finance & CAO | Sep 22, 2026 | Sale(10b5-1 plan) | −10,000 | $20.95 | $209.50K | 0 |
| Peter B. Cancelmo VP, General Counsel | Aug 31, 2026 | Option exercise | +25,000 | $2.94 | $73.50K | 25,200 |
| Peter B. Cancelmo VP, General Counsel | Aug 31, 2026 | Sale | −25,000 | $18.54 | $463.50K | 200 |
| Peter B. Cancelmo VP, General Counsel | Aug 28, 2026 | Sale | −25,000 | $18.65 | $466.25K | 200 |
| Peter B. Cancelmo VP, General Counsel | Aug 28, 2026 | Option exercise | +25,000 | $2.94 | $73.50K | 25,200 |
| Arnold C. Hanish Director | Aug 27, 2026 | Option exercise | +2,500 | $15.81 | $39.53K | 2,500 |
| Arnold C. Hanish Director | Aug 27, 2026 | Sale | −5,000 | $18.88 | $94.40K | 5,000 |
| Arnold C. Hanish Director | Aug 27, 2026 | Option exercise | +7,500 | $14.66 | $109.95K | 10,000 |
| Arnold C. Hanish Director | Aug 27, 2026 | Sale | −5,000 | $19.02 | $95.10K | 0 |
| Arnold C. Hanish Director | Aug 26, 2026 | Option exercise | +5,000 | $15.81 | $79.05K | 5,000 |
| Arnold C. Hanish Director | Aug 26, 2026 | Sale | −5,000 | $18.53 | $92.65K | 0 |
| David J. Borges VP, Finance & CAO | Aug 24, 2026 | Option exercise | +906 | $2.94 | $2.66K | 906 |
| David J. Borges VP, Finance & CAO | Aug 24, 2026 | Sale(10b5-1 plan) | −906 | $19.10 | $17.30K | 0 |
| David J. Borges VP, Finance & CAO | Aug 21, 2026 | Option exercise | +4,094 | $2.94 | $12.04K | 10,000 |
| David J. Borges VP, Finance & CAO | Aug 21, 2026 | Sale(10b5-1 plan) | −10,000 | $18.95 | $189.50K | 0 |
| David J. Borges VP, Finance & CAO | Aug 21, 2026 | Option exercise | +5,906 | $3.93 | $23.21K | 5,906 |
| Thomas J. Cable Director | Aug 20, 2026 | Option exercise | +7,500 | $3.93 | $29.48K | 50,067 |
| Thomas J. Cable Director | Aug 20, 2026 | Sale | −15,000 | $18.45 | $276.75K | 35,067 |
| Thomas J. Cable Director | Aug 20, 2026 | Option exercise | +7,500 | $2.00 | $15.00K | 42,567 |
| David J. Borges VP, Finance & CAO | Aug 13, 2026 | Option exercise | +5,000 | $3.93 | $19.65K | 5,000 |
| David J. Borges VP, Finance & CAO | Aug 13, 2026 | Sale(10b5-1 plan) | −5,000 | $16.95 | $84.75K | 0 |
| Thomas J. Cable Director | May 22, 2026 | Option exercise | +7,500 | $10.84 | $81.30K | 42,567 |
| Thomas J. Cable Director | May 22, 2026 | Sale(10b5-1 plan) | −7,500 | $11.61 | $87.08K | 35,067 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Feb 18, 2026 | Option exercise | +400,000 | $10.27 | $4.11M | 1,826,986 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Feb 18, 2026 | Tax withholding | −357,678 | $11.93 | $4.27M | 1,469,308 |
| David J. Borges VP, Finance & CAO | Jan 13, 2026 | Sale | −30,000 | $12.31 | $369.30K | 0 |
| David J. Borges VP, Finance & CAO | Jan 13, 2026 | Option exercise | +30,000 | $3.06 | $91.80K | 30,000 |
| David J. Borges VP, Finance & CAO | Jan 12, 2026 | Sale | −30,000 | $12.72 | $381.60K | 0 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Oct 13, 2025 | Gift | −600,000 | – | – | 1,426,986 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Oct 13, 2025 | Gift | +300,000 | – | – | 300,000 |
| Gregory A. Demopulos MD Chairman, CEO & President, Director | Oct 13, 2025 | Gift | +300,000 | – | – | 300,000 |
| Gregory A. Demopulos MD Chairman, CEO & President | Nov 17, 2023 | Buy | +15,000 | $1.68 | $25.20K | 123,945 |
| Peter A. Demopulos MD Director | Nov 15, 2023 | Buy | +10,000 | $1.53 | $15.30K | 208,516 |
| Gregory A. Demopulos MD Chairman, CEO & President | Nov 14, 2023 | Award | +25,000 | $1.44 | $36.00K | 108,945 |
| Gregory A. Demopulos MD Chairman, CEO & President | Nov 13, 2023 | Award | +37,500 | $1.29 | $48.38K | 83,945 |
| Thomas F. Bumol Director | Sep 12, 2023 | Award | +10,000 | $3.31 | $33.10K | 10,000 |
| Thomas J. Cable Director | May 22, 2023 | Option exercise | +5,000 | $5.30 | $26.50K | 40,067 |
| Thomas J. Cable Director | May 22, 2023 | Sale | −5,000 | $6.53 | $32.65K | 35,067 |
| Arnold C. Hanish Director | May 22, 2023 | Sale | −5,000 | $6.46 | $32.30K | 0 |
| Arnold C. Hanish Director | May 22, 2023 | Option exercise | +5,000 | $5.30 | $26.50K | 5,000 |
| Arnold C. Hanish Director | Sep 8, 2021 | Option exercise | +10,000 | $9.44 | $94.40K | 10,000 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 17, 2021 | Option exercise | +36,857 | $4.10 | $151.11K | 2,063,843 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 17, 2021 | Sale(10b5-1 plan) | −36,857 | $14.90 | $549.17K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 15, 2021 | Sale(10b5-1 plan) | −36,856 | $15.02 | $553.58K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Jun 15, 2021 | Option exercise | +36,856 | $4.10 | $151.11K | 2,063,842 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 20, 2021 | Sale(10b5-1 plan) | −36,856 | $14.96 | $551.37K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 20, 2021 | Option exercise | +36,856 | $4.10 | $151.11K | 2,063,842 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 19, 2021 | Option exercise | +36,857 | $4.10 | $151.11K | 2,063,843 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | May 19, 2021 | Sale(10b5-1 plan) | −36,857 | $17.07 | $629.15K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 8, 2021 | Sale(10b5-1 plan) | −35,206 | $17.76 | $625.26K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 8, 2021 | Option exercise | +35,206 | $4.10 | $144.34K | 2,062,192 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 7, 2021 | Sale(10b5-1 plan) | −37,407 | $17.91 | $669.96K | 2,026,986 |
| Gregory A. Demopulos MD CHAIRMAN, CEO & PRESIDENT, Director | Apr 7, 2021 | Option exercise | +37,407 | $4.10 | $153.37K | 2,064,393 |
| Michael A. Jacobsen VP FINANCE AND CAO | Feb 22, 2021 | Option exercise | +8,100 | $10.27 | $83.19K | 22,100 |
| Michael A. Jacobsen VP FINANCE AND CAO | Feb 22, 2021 | Sale(10b5-1 plan) | −8,100 | $23.28 | $188.57K | 14,000 |
| Peter A. Demopulos MD Director | Feb 22, 2021 | Option exercise | +5,000 | $5.30 | $26.50K | 193,516 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Borges David Officer | Sep 23, 2026 | 14,927 | $314.21K | Sep 23, 2026 | Exercise of Stock Options |
| Borges David Officer | Sep 22, 2026 | 10,000 | $184.90K | Sep 22, 2026 | Exercise of Stock Options |
| Cancelmo Peter Officer | Aug 31, 2026 | 25,000 | $463.54K | Aug 31, 2026 | Exercise of Options Under a Registered Plan |
| Cancelmo Peter Officer | Aug 28, 2026 | 25,000 | $466.13K | Aug 28, 2026 | Exercise of Options Under a Registered Plan |
| Hanish Arnold Director | Aug 27, 2026 | 10,000 | $189.46K | Aug 27, 2026 | Exercise of Options Under a Registered Plan |
| Hanish Arnold Director | Aug 26, 2026 | 5,000 | $94.13K | Aug 26, 2026 | Exercise of Options Under a Registered Plan |
| Borges David Officer | Aug 21, 2026 | 10,906 | $203.18K | Aug 21, 2026 | Exercise of Stock Options |
| Cable Thomas Director | Aug 20, 2026 | 15,000 | $276.77K | Aug 20, 2026 | Exercise of Options Under a Registered Plan |
| Borges David Officer | Aug 13, 2026 | 5,000 | $68.55K | Aug 13, 2026 | Exercise of Stock Options |
| Cable Thomas Director | May 22, 2026 | 7,500 | $89.70K | May 22, 2026 | Exercise of Stock Options |
| J. Borges David Officer | Jan 13, 2026 | 30,000 | $369.32K | Jan 13, 2026 | Exercise of options under a registered plan |
| J. Borges David Officer | Jan 12, 2026 | 30,000 | $381.60K | Jan 12, 2026 | Open Market Purchase |
| Zumwalt Kurt Officer | Sep 20, 2023 | 7,500 | $22.67K | Sep 20, 2023 | Exercise of options under a registered plan |
| J. Cable Thomas Director | May 22, 2023 | 5,000 | $32.67K | May 22, 2023 | Exercise of options under a registered plan |
| Hanish Arnold Director | May 22, 2023 | 5,000 | $32.29K | May 22, 2023 | Exercise of options under a registered plan |